TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference

Rhea-AI Summary

CAMBRIDGE, Mass., Feb. 09, 2022 – TCR² Therapeutics Inc. (Nasdaq: TCRR) will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 1:40 PM ET. The session will be held virtually, and a live webcast can be accessed on the Company’s Investors page at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the event.

TCR² is focused on innovative T cell therapies targeting solid tumors.

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contacts:

TCR² Therapeutics

Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What event is TCRR participating in on February 16, 2022?

TCRR will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET.

Where can I watch the TCRR presentation live?

The live webcast of the TCRR presentation will be available on the Company’s Investors page at www.investors.tcr2.com.

How long will the TCRR presentation replay be available?

The archived replay of the TCRR presentation will be available for at least 30 days after the event.

What is TCRR's focus in cell therapy?

TCRR focuses on developing novel T cell therapies for cancer patients with solid tumors using its proprietary TRuC platform.